Research graph
References from The cost-effectiveness of medical versus surgical androgen deprivation therapy for advanced prostate cancer in Tanzania: a Markov model-based analysis. Local targets link to admitted publications; unresolved targets remain external evidence.
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2021 · External reference
Patients’ pathways to cancer care in Tanzania: documenting and addressing social inequalities in reaching a cancer diagnosis
10.1186/s12913-021-07438-5 · 2022 · External reference
Estimating cost of prostate cancer management: an experience from Tanzania
10.1186/s12301-024-00422-5 · 2024 · External reference
Cost-effectiveness of androgen suppression therapies in advanced prostate cancer
10.1093/jnci/92.21.1731 · 2000 · External reference
Comparative study of surgical orchidectomy and medical castration in treatment efficacy, adverse effects and cost based on a large prospective metastatic prostate cancer registry
10.1016/j.urolonc.2020.05.005 · 2020 · External reference
Examining differences in pathological outcomes and safety for prostate cancer patients undergoing either subcapsular orchiectomy or medical androgen deprivation therapy: a systematic review
2025 · External reference
Cancer in sub-Saharan Africa: a lancet oncology commission
10.1016/s1470-2045(21)00720-8 · 2022 · External reference
Management of advanced prostate cancer in a middle-income country: real-world consideration of the advanced prostate cancer consensus conference 2017
10.1111/bju.14807 · 2019 · External reference
Knowledge, perceived risk and utilization of prostate Cancer screening services among men in Dar Es Salaam, Tanzania
10.1155/2019/2463048 · 2019 · External reference
Cancer mortality patterns in Tanzania: a retrospective hospital-based study, 2006-2015
10.1200/jgo.19.00270 · 2006 · External reference
Prostate cancer awareness and screening among men in a rural community in Kenya: a cross-sectional study
10.1186/s12301-020-00108-8 · 2021 · External reference
Cost-effectiveness of systemic treatments for metastatic castration-sensitive prostate Cancer: an economic evaluation based on network meta-analysis
10.1016/j.jval.2021.10.016 · 2022 · External reference
Cost effectiveness of treatment strategies for high risk prostate cancer
10.1002/cncr.34450 · 2022 · External reference
Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer
10.1371/journal.pone.0277282 · 2022 · External reference
Unresolved reference
2015 · External reference
Cost-effectiveness of adding androgen deprivation therapy to radiation therapy for men with advanced prostate cancer from a U.S. payer’s perspective
10.18553/jmcp.2019.25.2.225 · 2019 · External reference
Advances in cost-effectiveness analysis of health interventions
2000 · External reference
Consolidated health economic evaluation reporting standards (CHEERS) statement
10.1186/1478-7547-11-6 · 2013 · External reference
Occupation-based life expectancy: actuarial fairness in determining statutory retirement age
10.3389/fsoc.2021.675618 · 2021 · External reference
Unresolved reference
2023 · External reference
Unresolved reference
2023 · External reference
Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness
10.1111/j.1349-7006.2010.01774.x · 2011 · External reference
The patient’s choice of androgen-deprivation therapy in locally advanced prostate cancer: bicalutamide, a gonadotrophin-releasing hormone analogue or orchidectomy
10.1111/j.1464-410x.2005.05802.x · 2005 · External reference
Barriers to prostate Cancer care: affordable care is not enough
10.1177/1049732312467852 · 2013 · External reference
Health care integration and quality among men with prostate Cancer
10.1016/j.juro.2016.07.040 · 2017 · External reference
Quality of Cancer Care in Tanzania as experienced by patients: a qualitative study
10.1177/23779608231157332 · 2023 · External reference
Monitoring and evaluating Progress towards universal health coverage in Tanzania
10.1371/journal.pmed.1001698 · 2014 · External reference
Unresolved reference
2023 · External reference
Progressive pathway to universal health coverage in Tanzania: a call for preferential resource allocation targeting the poor progressive pathway to universal health coverage in Tanzania: a call for preferential resource allocation targeting the poor
10.1080/23288604.2018.1513268 · 2018 · External reference
OSIRIS: a minimum data set for data sharing and interoperability in oncology
10.1200/cci.20.00094 · 2021 · External reference
Natural history of progression after PSA elevation following radical prostatectomy
10.1001/jama.281.17.1591 · 1999 · External reference
A Markov model of the natural history of prostate cancer
10.1016/0895-4356(94)90029-9 · 1994 · External reference
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
10.1056/nejm198908173210702 · 1989 · External reference
The Veterans Administration Cooperative Urological Research Group’s studies of cancer of the prostate
10.1002/1097-0142(197311)32:5<1126::aid-cncr2820320518>3.0.co;2-c · 1973 · External reference
Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies
1988 · External reference
Natural history of progression after PSA elevation following radical prostatectomy
10.1001/jama.281.17.1591 · ExternalCitation · doi-reference
The Veterans Administration Cooperative Urological Research Group’s studies of cancer of the prostate
10.1002/1097-0142(197311)32:5<1126::aid-cncr2820320518>3.0.co;2-c · ExternalCitation · doi-reference
Cost effectiveness of treatment strategies for high risk prostate cancer
10.1002/cncr.34450 · ExternalCitation · doi-reference
A Markov model of the natural history of prostate cancer
10.1016/0895-4356(94)90029-9 · ExternalCitation · doi-reference
Health care integration and quality among men with prostate Cancer
10.1016/j.juro.2016.07.040 · ExternalCitation · doi-reference
Cost-effectiveness of systemic treatments for metastatic castration-sensitive prostate Cancer: an economic evaluation based on network meta-analysis
10.1016/j.jval.2021.10.016 · ExternalCitation · doi-reference
Comparative study of surgical orchidectomy and medical castration in treatment efficacy, adverse effects and cost based on a large prospective metastatic prostate cancer registry
10.1016/j.urolonc.2020.05.005 · ExternalCitation · doi-reference
Cancer in sub-Saharan Africa: a lancet oncology commission
10.1016/s1470-2045(21)00720-8 · ExternalCitation · doi-reference
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
10.1056/nejm198908173210702 · ExternalCitation · doi-reference
Progressive pathway to universal health coverage in Tanzania: a call for preferential resource allocation targeting the poor progressive pathway to universal health coverage in Tanzania: a call for preferential resource allocation targeting the poor
10.1080/23288604.2018.1513268 · ExternalCitation · doi-reference
Cost-effectiveness of androgen suppression therapies in advanced prostate cancer
10.1093/jnci/92.21.1731 · ExternalCitation · doi-reference
Management of advanced prostate cancer in a middle-income country: real-world consideration of the advanced prostate cancer consensus conference 2017
10.1111/bju.14807 · ExternalCitation · doi-reference
Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness
10.1111/j.1349-7006.2010.01774.x · ExternalCitation · doi-reference
The patient’s choice of androgen-deprivation therapy in locally advanced prostate cancer: bicalutamide, a gonadotrophin-releasing hormone analogue or orchidectomy
10.1111/j.1464-410x.2005.05802.x · ExternalCitation · doi-reference
Knowledge, perceived risk and utilization of prostate Cancer screening services among men in Dar Es Salaam, Tanzania
10.1155/2019/2463048 · ExternalCitation · doi-reference
Barriers to prostate Cancer care: affordable care is not enough
10.1177/1049732312467852 · ExternalCitation · doi-reference
Quality of Cancer Care in Tanzania as experienced by patients: a qualitative study
10.1177/23779608231157332 · ExternalCitation · doi-reference
Consolidated health economic evaluation reporting standards (CHEERS) statement
10.1186/1478-7547-11-6 · ExternalCitation · doi-reference
Prostate cancer awareness and screening among men in a rural community in Kenya: a cross-sectional study
10.1186/s12301-020-00108-8 · ExternalCitation · doi-reference
Estimating cost of prostate cancer management: an experience from Tanzania
10.1186/s12301-024-00422-5 · ExternalCitation · doi-reference
Patients’ pathways to cancer care in Tanzania: documenting and addressing social inequalities in reaching a cancer diagnosis
10.1186/s12913-021-07438-5 · ExternalCitation · doi-reference
OSIRIS: a minimum data set for data sharing and interoperability in oncology
10.1200/cci.20.00094 · ExternalCitation · doi-reference
Cancer mortality patterns in Tanzania: a retrospective hospital-based study, 2006-2015
10.1200/jgo.19.00270 · ExternalCitation · doi-reference
Monitoring and evaluating Progress towards universal health coverage in Tanzania
10.1371/journal.pmed.1001698 · ExternalCitation · doi-reference
Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer
10.1371/journal.pone.0277282 · ExternalCitation · doi-reference
Cost-effectiveness of adding androgen deprivation therapy to radiation therapy for men with advanced prostate cancer from a U.S. payer’s perspective
10.18553/jmcp.2019.25.2.225 · ExternalCitation · doi-reference
Occupation-based life expectancy: actuarial fairness in determining statutory retirement age
10.3389/fsoc.2021.675618 · ExternalCitation · doi-reference
